Ranked #3,565 of 8,699 institutional investors
Stempoint Capital LP
New York, NY
$520M
US stock portfolio at live prices · today +$2.0M (+0.38%)
Market closed. Prices as of Nov 20, 6:11 AM ET
- Value at quarter end (Q3 2026)
- $558M
- Change from Q2 2026
- −$19.5M (−3.37%)
- Positions
- 68 · 34 new, 25 sold out
- Filed
- Nov 16, 2026
Not counted in the ranking: call options on $354K of stock, put options on $763K. $87.6M of holdings we could not match to a US listing are included at their reported quarter-end value.
Holdings
Q3 2026 13F, live pricesSRRK 6.67%ERAS 6.18%TRAX 5.55%ABVX 4.33%TNGX 4.32%
| Stock | Shares | Value, live | % of portfolio | vs Q2 2026 |
|---|---|---|---|---|
| SRRK Scholar Rock Holding Corporation | 688,954 | $34.7M | 6.67% | Added +188% |
| ERAS Erasca, Inc. | 2,260,594 | $32.1M | 6.18% | Added +44% |
| TRAX First Tracks Biotherapeutics, Inc. | 649,924 | $28.9M | 5.55% | Added +4% |
| ABVX ABIVAX Société Anonyme | 279,398 | $22.5M | 4.33% | Reduced −2% |
| TNGX Tango Therapeutics, Inc. | 989,345 | $22.5M | 4.32% | Reduced −19% |
| ELVN Enliven Therapeutics, Inc. | 330,476 | $15.3M | 2.95% | Reduced −5% |
| ADPT Adaptive Biotechnologies Corporation | 463,551 | $13.0M | 2.50% | New |
| SYRE Spyre Therapeutics, Inc. | 132,238 | $12.9M | 2.48% | Added +24% |
| SRZN Surrozen, Inc. | 418,527 | $12.8M | 2.47% | Reduced −31% |
| DNTH Dianthus Therapeutics, Inc. | 150,776 | $12.8M | 2.46% | Reduced −25% |
| PRAX Praxis Precision Medicines, Inc. | 38,720 | $12.0M | 2.31% | Added +4% |
| ONC BeOne Medicines AG | 25,051 | $10.0M | 1.92% | New |
| LLY Eli Lilly and Company | 6,599 | $8.9M | 1.71% | New |
| GRAL GRAIL, Inc. | 81,924 | $8.6M | 1.65% | New |
| XENE Xenon Pharmaceuticals Inc. | 222,287 | $8.3M | 1.60% | Added +192% |
| CCCC C4 Therapeutics, Inc. | 3,293,376 | $8.0M | 1.54% | Added +529% |
| JNJ Johnson & Johnson | 30,000 | $8.0M | 1.54% | New |
| RVMD Revolution Medicines, Inc. | 50,000 | $8.0M | 1.53% | Reduced −69% |
| TRVI Trevi Therapeutics, Inc. | 552,245 | $7.6M | 1.46% | New |
| CYTK Cytokinetics, Incorporated | 145,760 | $7.5M | 1.44% | Added +93% |
| ACRS Aclaris Therapeutics, Inc. | 2,050,698 | $7.2M | 1.38% | New |
| JBIO Jade Biosciences, Inc. | 471,718 | $7.1M | 1.37% | New |
| IMVT Immunovant, Inc. | 201,334 | $6.5M | 1.26% | Reduced −27% |
| OABI OmniAb, Inc. | 1,204,038 | $6.1M | 1.16% | New |
| VRDN Viridian Therapeutics, Inc. | 187,320 | $5.9M | 1.13% | New |
| CERS Cerus Corporation | 2,967,942 | $5.6M | 1.08% | New |
| COGT Cogent Biosciences, Inc. | 184,173 | $5.1M | 0.98% | New |
| GH Guardant Health, Inc. | 33,527 | $4.9M | 0.94% | New |
| ARWR Arrowhead Pharmaceuticals, Inc. | 109,926 | $4.8M | 0.92% | Added +180% |
| SNY Sanofi | 99,880 | $4.6M | 0.88% | New |
| EWTX Edgewise Therapeutics, Inc. | 111,577 | $4.6M | 0.88% | New |
| AURA Aura Biosciences, Inc. | 647,406 | $4.5M | 0.87% | Reduced −9% |
| CGON CG Oncology, Inc. | 54,791 | $4.5M | 0.86% | Reduced −66% |
| VOR Vor Biopharma Inc. | 200,836 | $3.7M | 0.71% | New |
| LBRX LB Pharmaceuticals Inc | 91,757 | $3.7M | 0.71% | Added +189% |
| FTH Faeth Therapeutics, Inc. | 404,921 | $3.5M | 0.68% | New |
| BNTX BioNTech SE | 42,200 | $3.4M | 0.66% | New |
| AVLN Avalyn Pharma Inc. | 118,000 | $3.4M | 0.65% | Unchanged |
| IPSC Century Therapeutics, Inc. | 2,563,862 | $3.4M | 0.65% | Added +19% |
| ISRG Intuitive Surgical, Inc. | 8,087 | $3.3M | 0.63% | New |
| CELC Celcuity Inc. | 57,880 | $3.3M | 0.63% | Reduced −41% |
| IDYA IDEAYA Biosciences, Inc. | 123,760 | $3.2M | 0.62% | New |
| OVID Ovid Therapeutics Inc. | 1,287,804 | $3.0M | 0.58% | Reduced −47% |
| MLYS Mineralys Therapeutics, Inc. | 200,000 | $2.8M | 0.54% | Reduced −67% |
| INSM Insmed Incorporated | 19,603 | $2.8M | 0.54% | New |
| ORKA Oruka Therapeutics, Inc. | 27,260 | $2.7M | 0.51% | Reduced −77% |
| UTHR United Therapeutics Corporation | 4,646 | $2.6M | 0.50% | New |
| DYN Dyne Therapeutics, Inc. | 154,234 | $2.5M | 0.48% | New |
| ATTO Attovia Therapeutics, Inc. | 138,200 | $2.2M | 0.41% | New |
| NRIX Nurix Therapeutics, Inc. | 137,973 | $1.9M | 0.36% | New |
| EDSA Edesa Biotech, Inc. | 825,000 | $1.8M | 0.34% | New |
| ARQT Arcutis Biotherapeutics, Inc. | 61,189 | $1.7M | 0.32% | Reduced −38% |
| MNPR Monopar Therapeutics Inc. | 23,302 | $1.6M | 0.31% | Reduced −23% |
| WHWK Whitehawk Therapeutics, Inc. | 495,980 | $1.5M | 0.30% | Reduced −51% |
| WGS GeneDx Holdings Corp. | 29,275 | $1.4M | 0.28% | New |
| BDSX Biodesix, Inc. | 141,548 | $1.2M | 0.23% | Added +102% |
| AEMD Aethlon Medical, Inc. | 213,685 | $1.0M | 0.20% | New |
| SABS SAB Biotherapeutics, Inc. | 352,689 | $1.0M | 0.20% | Added +3% |
| QNRX Quoin Pharmaceuticals, Ltd. | 236,234 | $794K | 0.15% | New |
| ADRX ADARx Pharmaceuticals, Inc. | 52,000 | $736K | 0.14% | New |
| ANRO Alto Neuroscience Inc | 21,763 | $577K | 0.11% | New |
| STLN Starling Oncology, Inc. | 156,663 | $498K | <0.1% | New |
| CUE Cue Biopharma, Inc. | 108,647 | $489K | <0.1% | Added +62% |
| CLRB Cellectar Biosciences, Inc. | 447,360 | $395K | <0.1% | Added +26% |
| CALC CalciMedica, Inc. | 248,972 | $291K | <0.1% | New |
| BRVE Braveheart Bio, Inc. | 10,000 | $193K | <0.1% | New |
| RLMD Relmada Therapeutics, Inc. | 44,129 | $137K | <0.1% | Reduced −97% |
| VTGN Vistagen Therapeutics, Inc. | 80,299 | $15K | <0.1% | Added +5% |
Sold out in Q3 2026
| Stock | Shares held at Q2 2026 | Worth today |
|---|---|---|
| TYRA Tyra Biosciences, Inc. | 632,754 | $12.5M |
| AMLX Amylyx Pharmaceuticals, Inc. | 384,304 | $10.1M |
| KOD Kodiak Sciences Inc. | 75,872 | $7.4M |
| CLYM Climb Bio Inc | 742,745 | $6.9M |
| CLDX Celldex Therapeutics, Inc. | 178,412 | $5.0M |
| IVA Inventiva S.A. | 1,426,320 | $4.9M |
| DFTX Definium Therapeutics, Inc. | 137,124 | $4.0M |
| ASMB Assembly Biosciences, Inc. | 170,378 | $3.8M |
| PSNL Personalis, Inc. | 247,783 | $3.6M |
| ACAD Acadia Pharmaceuticals Inc. | 143,167 | $2.5M |
| CMPS COMPASS Pathways plc | 284,769 | $2.5M |
| SLDB Solid Biosciences Inc. | 358,780 | $2.3M |
| EQ Equillium, Inc. | 2,016,607 | $2.3M |
| BIOA BioAge Labs, Inc. | 464,171 | $2.2M |
| AXSM Axsome Therapeutics, Inc. | 15,375 | $2.1M |
| PTGX Protagonist Therapeutics, Inc. | 16,303 | $2.0M |
| SPRB Spruce Biosciences, Inc. | 41,388 | $1.7M |
| RAPP Rapport Therapeutics, Inc. | 66,582 | $1.6M |
| GLUE Monte Rosa Therapeutics, Inc. | 153,544 | $1.4M |
| MPLT MapLight Therapeutics, Inc. | 106,906 | $686K |
| GPCR Structure Therapeutics Inc. | 38,178 | $654K |
| ALMS Alumis Inc. | 135,736 | $588K |
| SION Sionna Therapeutics, Inc. | 59,426 | $176K |
| TENX Tenax Therapeutics, Inc. | 96,273 | $134K |
| EYPT EyePoint, Inc. | 338,471 | $89K |